Eczema Awareness Month

Dermatology Times recaps Eczema Awareness Month with expert insights on disease burden, individualized treatment, systemic therapies, and gaps in care access.

Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.

Feldman challenges common eczema myths and highlights the disease’s effects on sleep, mental health, treatment adherence, and quality of life.

Stratman discusses individualized eczema care, expanding treatment options, and the potential of precision medicine to guide therapy.

Christopher Bunick, MD, PhD, presented long-term safety data for JAK inhibitors upadacitinib and abrocitinib in atopic dermatitis at Fall Clinical 2026.

At Fall Clinical 2026, Raj Chovatiya, MD, PhD, MSCI, urged clinicians to understand the data and consider systemic therapy in atopic dermatitis.

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), reviews how state-level data from the NEA's State of AD 2026 National Indicator Report can inform access to atopic dermatitis care.

Tenesha Wallace Hood, MA, of the National Eczema Association (NEA), discusses diagnosed prevalence of AD and care access findings from the NEA's State of AD 2026 report.

A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.